Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Medtronic plc (NYSE: MDT) announced advancements in its extended wear infusion set technology during the American Diabetes Association's 80th Scientific Sessions. This new infusion set can be used safely for up to 7 days, more than twice the lifespan of current 3-day sets. Clinical studies indicate improved insulin stability, reducing the risk of hyperglycemia. Patients can potentially save 5-10 vials of insulin annually. The product has received the CE Mark, and a pivotal trial in the U.S. is underway to study its safety and efficacy.
Medtronic has announced a significant funding agreement with Blackstone Life Sciences to enhance its research and development in diabetes management. The collaboration will provide $337 million over several years, focusing on innovative insulin delivery and sensor technologies. This investment aims to address unmet needs for the 22 million global Type 1 diabetes patients. Medtronic plans to fast-track multiple development programs while the funding will cover R&D expenses, with potential royalties in the low- to mid-single digits if commercialized.
Medtronic announced positive results from two pivotal clinical trials for its MiniMed™ 780G automated insulin pump aimed at improving Type 1 diabetes management. The U.S. trial, focusing on ages 14-75, showed 96% user satisfaction, no severe hypoglycemia, and an average A1C of 7.0%. A New Zealand trial highlighted a 13-point boost in Time in Range for less-controlled patients. Bluetooth connectivity for real-time glucose monitoring is also a feature. The findings will support an upcoming FDA Premarket Approval application.
Medtronic (NYSE:MDT) has received CE Marking for its MiniMed™ 780G insulin pump, designed for type 1 diabetes patients aged 7 to 80. This system automates insulin delivery via the SmartGuard™ algorithm, providing basal insulin and correction boluses every five minutes. It allows customizable glucose targets and features Bluetooth connectivity for real-time glucose monitoring. Clinical feedback highlights improved diabetes management and quality of life. The MiniMed 780G is set to ship in select European markets this fall but is still under investigation in the U.S.
Medtronic (NYSE:MDT) announced participation in the American Diabetes Association's 80th Scientific Sessions, running from June 12-16, 2020. The company will present 16 data presentations, including a symposium on its Advanced Hybrid Closed-Loop Systems and related technologies. Medtronic's virtual exhibit will showcase innovations in diabetes technology and telehealth support. The presentation aims to highlight clinical outcomes and differentiated support offerings, focusing on improved diabetes management.
Medtronic has received CE Mark approval for a one-month dual antiplatelet therapy (DAPT) indication for high bleeding risk (HBR) patients implanted with its Resolute Onyx™ Drug-Eluting Stent. This first-of-its-kind global approval allows shorter DAPT regimens for HBR patients, which comprise nearly 40% of all PCI patients. The decision is based on the Onyx ONE Global Study, demonstrating non-inferior outcomes compared to a competitive device. Medtronic aims to secure similar approval in the U.S. after submitting relevant data to the FDA.
Medtronic plc (NYSE: MDT) will participate in the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020. CEO Geoff Martha will speak starting at 8:00 a.m. EDT. A live audio webcast will be accessible on Medtronic's Investor Relations site, with an archive available later the same day. Medtronic, headquartered in Dublin, is a global leader in medical technology, employing over 90,000 people and serving more than 150 countries.
Medtronic (NYSE: MDT) announced its participation in the Jefferies 2020 Global Healthcare Conference on June 3, 2020. Karen Parkhill, the CFO, will address questions at 2:30 p.m. EDT. A live audio webcast will be accessible via the Investor Events link on the Medtronic investor relations page, with a replay available later the same day. Medtronic operates globally, employing over 90,000 people and serving patients in more than 150 countries, focusing on advancing healthcare solutions.
Medtronic (NYSE: MDT) announced its participation in the Bernstein 36th Annual Strategic Decisions Conference on May 29, 2020. CEO Geoff Martha will present and address questions starting at 9:00 a.m. EDT. The event will be held virtually and can be accessed through the Investor Events link on Medtronic's investor relations page. An archive of the presentation will be available later that day. Medtronic is a leader in medical technology, operating in over 150 countries and focused on improving global healthcare.
Medtronic (NYSE: MDT) announced FDA approval for the Android version of its Guardian Connect continuous glucose monitoring (CGM) system. This system alerts users of potential high or low glucose events up to 60 minutes in advance and aims to enhance the diabetes management experience. The Guardian Connect app will introduce features such as an in-app Startup Wizard and customizable alert functions. A real-world study showed that predictive alerts helped patients avoid 65% of low glucose excursions. Updated systems are expected to ship in summer 2020.